Stewart & Patten Co. LLC trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 1.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 199,941 shares of the company’s stock after selling 2,191 shares during the period. Johnson & Johnson makes up about 5.3% of Stewart & Patten Co. LLC’s portfolio, making the stock its biggest position. Stewart & Patten Co. LLC’s holdings in Johnson & Johnson were worth $25,802,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Johnson & Johnson by 1.5% in the third quarter. Vanguard Group Inc. now owns 213,433,449 shares of the company’s stock worth $29,490,100,000 after buying an additional 3,235,861 shares during the period. Vanguard Group Inc increased its holdings in Johnson & Johnson by 1.5% during the 3rd quarter. Vanguard Group Inc now owns 213,433,449 shares of the company’s stock worth $29,490,100,000 after purchasing an additional 3,235,861 shares during the period. Bank of New York Mellon Corp increased its holdings in Johnson & Johnson by 1.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 33,892,560 shares of the company’s stock worth $4,682,935,000 after purchasing an additional 435,564 shares during the period. Morgan Stanley increased its holdings in Johnson & Johnson by 6.3% during the 3rd quarter. Morgan Stanley now owns 22,920,470 shares of the company’s stock worth $3,166,921,000 after purchasing an additional 1,352,484 shares during the period. Finally, Legal & General Group Plc increased its holdings in Johnson & Johnson by 1.4% during the 3rd quarter. Legal & General Group Plc now owns 12,824,479 shares of the company’s stock worth $1,771,956,000 after purchasing an additional 173,991 shares during the period. 67.32% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE JNJ opened at $138.02 on Wednesday. The company has a current ratio of 1.47, a quick ratio of 1.20 and a debt-to-equity ratio of 0.46. The firm has a market cap of $370.29 billion, a price-to-earnings ratio of 16.87, a P/E/G ratio of 2.21 and a beta of 0.68. Johnson & Johnson has a 12-month low of $118.62 and a 12-month high of $148.99.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.06 by $0.04. The business had revenue of $20.02 billion for the quarter, compared to analysts’ expectations of $19.55 billion. Johnson & Johnson had a return on equity of 35.63% and a net margin of 18.75%. The business’s revenue for the quarter was up .1% on a year-over-year basis. During the same quarter last year, the firm earned $2.06 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 8.58 EPS for the current year.

Several research analysts have commented on the company. Zacks Investment Research restated a “sell” rating on shares of Johnson & Johnson in a report on Monday, December 31st. Morgan Stanley reduced their price objective on Johnson & Johnson from $153.00 to $130.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 2nd. Barclays restated an “equal weight” rating and set a $135.00 price objective (down from $137.00) on shares of Johnson & Johnson in a report on Wednesday, January 23rd. Wells Fargo & Co restated an “outperform” rating and set a $152.00 price objective (down from $162.00) on shares of Johnson & Johnson in a report on Monday, January 14th. Finally, Citigroup raised their price objective on Johnson & Johnson from $139.00 to $147.00 and gave the stock a “neutral” rating in a report on Monday, February 25th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $143.58.

COPYRIGHT VIOLATION WARNING: “Johnson & Johnson (JNJ) Shares Sold by Stewart & Patten Co. LLC” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://theolympiareport.com/2019/04/17/johnson-johnson-jnj-shares-sold-by-stewart-patten-co-llc.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: What Does Beta Mean In Stock Selection

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.